Deauville score Introduction (What it is)
Deauville score is a standardized way to interpret FDG PET imaging in oncology.
It compares how much a suspected cancer area “lights up” versus normal reference tissues.
It is most commonly used in lymphoma, especially Hodgkin lymphoma and some non-Hodgkin lymphomas.
Clinicians use it to describe treatment response in a consistent, shared language.
Why Deauville score used (Purpose / benefits)
FDG PET scans show how tissues use glucose-like tracer, which often reflects metabolic activity. Many cancers—particularly lymphomas—can be metabolically active, but PET images can be hard to compare across time, readers, or institutions if reports rely only on subjective wording such as “improved” or “residual uptake.”
Deauville score helps solve that communication problem by providing an ordered scale that ties uptake in a lesion to uptake in normal reference regions (commonly the mediastinal blood pool and the liver). In practice, this supports:
- Standardized response assessment: Helps clinicians describe whether uptake is lower than, similar to, or higher than reference tissues.
- Consistency across scans: Makes it easier to compare baseline, interim, and end-of-treatment PET findings.
- Multidisciplinary coordination: A shared scoring system can streamline discussions among oncology, radiology/nuclear medicine, hematology, radiation oncology, and surgical teams.
- Clinical trial alignment: Many lymphoma trials and response criteria incorporate Deauville score, supporting reproducible endpoints.
- Risk-adapted thinking (where applicable): In some diseases and protocols, interim PET response may be considered alongside clinical factors to frame next-step options. How it is used varies by cancer type and stage, and by clinician and case.
Deauville score is not a stand-alone diagnosis and does not replace pathology, clinical examination, or other imaging. It is one piece of an overall oncology assessment.
Indications (When oncology clinicians use it)
Clinicians typically use Deauville score in scenarios such as:
- Baseline and follow-up FDG PET/CT for FDG-avid lymphomas to document response patterns over time
- Interim PET during therapy in selected lymphoma treatment pathways (use varies by clinician and case)
- End-of-treatment PET to assess metabolic response after completing a planned course of therapy
- Post-treatment surveillance questions when there is clinical concern for relapse (approaches vary by institution)
- Assessing residual masses on CT where scar tissue versus active disease is uncertain
- Research and clinical trials requiring standardized PET response reporting
- Planning consolidative radiation in some cases when combined with other clinical factors (varies by protocol)
Contraindications / when it’s NOT ideal
Deauville score is a reporting method, not a treatment. Its usefulness depends on whether FDG PET is appropriate and interpretable for the clinical question. Situations where it may be less suitable or where another approach may be preferred include:
- Cancers that are not reliably FDG-avid: Some tumor types or subtypes may show low FDG uptake, reducing PET’s value. This varies by cancer type and biology.
- High likelihood of false positives from inflammation or infection: Recent surgery, active infection, inflammatory diseases, or healing tissues can increase FDG uptake.
- Poor scan conditions that degrade accuracy: Uncontrolled blood glucose, significant patient motion, or technical limitations can reduce interpretability.
- Timing too close to therapy: Recent chemotherapy, immunotherapy, radiation therapy, or growth factor support can alter uptake patterns; optimal timing varies by clinician and case.
- Pregnancy considerations: PET involves ionizing radiation and is generally avoided in pregnancy unless strongly justified; alternatives may be considered.
- When anatomic detail is the priority: For certain questions (for example, local invasion or detailed organ anatomy), CT with contrast or MRI may be more informative.
- When tissue confirmation is needed: If results would change management and uncertainty is high, biopsy may be more appropriate than relying on imaging alone.
How it works (Mechanism / physiology)
Deauville score is based on FDG PET (often performed as PET/CT). FDG (fluorodeoxyglucose) is a glucose analog taken up by cells through glucose transporters and phosphorylated inside the cell. Many cancers—and many normal or inflamed tissues—can show increased glucose metabolism, leading to increased FDG uptake.
The Deauville approach interprets uptake in suspected disease sites relative to two internal reference regions:
- Mediastinal blood pool (a reference for low-to-moderate physiologic uptake)
- Liver (a reference for moderate physiologic uptake that is usually higher than mediastinum)
The score generally reflects a spectrum:
- Lower uptake than reference tissues suggests lower likelihood of active residual disease.
- Higher uptake than reference tissues can suggest residual active disease, but interpretation depends on context, pattern, and timing.
Deauville score does not have “onset” or “duration” like a medication. Instead, it reflects a snapshot of metabolic activity at the time of imaging. Its meaning is not permanent and can change with treatment response, infection/inflammation, or progression. Because FDG uptake is not cancer-specific, Deauville score is interpreted alongside symptoms, physical exam, laboratory findings, prior imaging, and sometimes biopsy.
Deauville score Procedure overview (How it’s applied)
Deauville score is not a stand-alone procedure; it is a structured way to report FDG PET findings. A high-level clinical workflow often looks like this:
-
Evaluation/exam
The oncology team reviews the diagnosis, stage, symptoms, and prior imaging. They clarify the clinical question, such as baseline staging, interim response, or end-of-treatment response. -
Imaging/labs preparation
Patients typically receive instructions for PET preparation (for example, fasting and blood glucose checks). The exact preparation depends on local protocols. -
Imaging (FDG PET/CT acquisition)
FDG is administered, followed by a waiting period, then scanning. CT may be used for anatomic correlation and attenuation correction, and sometimes as a diagnostic-quality CT depending on protocol. -
Staging and response framework
For lymphomas, PET results are often interpreted within a broader staging and response system (for example, Lugano criteria), which may incorporate Deauville score. -
Reporting with Deauville score
The interpreting clinician (often nuclear medicine or radiology) compares lesion uptake with mediastinum and liver and assigns a Deauville score for key sites or overall response, depending on the reporting style. -
Treatment planning discussion
The oncology team integrates PET findings with clinical status and other tests. How much weight Deauville score carries varies by lymphoma subtype, treatment plan, and institutional practice. -
Response assessment and follow-up
Repeat PET or other imaging may be considered in selected situations. Many patients transition to surveillance focused on symptoms, exam, and selective testing, which varies by clinician and case.
Types / variations
Deauville score is commonly described as a five-point scale used primarily in lymphoma PET interpretation. Variations exist in how it is documented and applied:
-
Interim (mid-treatment) Deauville score:
Used during a treatment course to describe metabolic response trends. Whether and how interim PET influences management varies by clinician and case, and by lymphoma subtype and protocol. -
End-of-treatment Deauville score:
Used after completing planned therapy to summarize metabolic response and help frame next-step considerations (for example, observation versus additional evaluation). -
Lesion-based vs overall (patient-level) reporting:
Some reports provide scores for several key lesions; others provide an overall score driven by the most FDG-avid residual site. -
Integration with formal response criteria:
In lymphoma, Deauville score is often embedded in broader response systems that combine PET results with CT measurements and clinical information. -
Adult vs pediatric considerations:
PET technique, reference uptake patterns, and differential diagnoses for FDG uptake can differ across age groups. Interpretation remains individualized. -
Special notations for atypical findings:
Reports may describe new lesions, diffuse uptake patterns, or sites where inflammation is a strong alternative explanation. Some systems include an “uncertain” concept, handled by narrative comments rather than a separate score in some practices.
Pros and cons
Pros:
- Standardizes PET response language across clinicians and centers
- Uses internal reference tissues, supporting consistency within a scan
- Helps communicate interim and end-of-treatment metabolic response clearly
- Fits well into lymphoma response frameworks used in routine care and research
- Can reduce ambiguity compared with purely descriptive PET reports
- Encourages careful correlation with anatomic imaging and clinical context
Cons:
- FDG uptake is not cancer-specific, so inflammation and infection can mimic disease
- Interpretation depends on timing, technique, and patient factors (for example, glucose levels)
- Some cancers or subtypes are less FDG-avid, limiting usefulness
- Borderline cases can still be subjective, especially near reference tissue uptake
- Residual uptake may not always equate to viable tumor, and low uptake may not always exclude it
- Over-reliance without clinical correlation can lead to misunderstanding of risk
- Not every care pathway uses Deauville score the same way, which can confuse patients reading reports
Aftercare & longevity
Because Deauville score is a way to interpret imaging rather than a treatment, “aftercare” mainly refers to what happens after a PET report is generated and how results are integrated into ongoing cancer care.
Common factors that influence how PET findings are used over time include:
- Cancer type and stage: FDG avidity and the meaning of residual uptake vary by disease. Lymphoma subtypes can behave differently.
- Tumor biology and treatment sensitivity: Some tumors show rapid metabolic response; others change more slowly.
- Timing of imaging: PET performed too soon after therapy can show temporary inflammatory uptake, while delayed imaging may show different patterns.
- Clinical status: Symptoms, physical exam findings, and lab results can raise or lower concern regardless of score.
- Quality and comparability of scans: Consistent preparation, scanner technique, and reporting approach help longitudinal interpretation.
- Comorbidities and inflammation risks: Autoimmune disease, infection risk, recent vaccinations, and post-surgical healing can complicate PET interpretation.
- Follow-up plan and survivorship care: Long-term care often includes monitoring for recurrence, late effects, and psychosocial needs. The role of repeat imaging varies by clinician and case and may be influenced by guidelines, prior findings, and patient-specific factors.
- Access to multidisciplinary expertise: Complex cases may benefit from tumor board review, especially when PET findings are equivocal.
In many settings, a Deauville score is treated as a structured summary that helps guide discussions, not a definitive answer by itself.
Alternatives / comparisons
Deauville score is one tool among many for assessing cancer status. Alternatives and complementary approaches are chosen based on the clinical question, cancer type, and patient factors.
-
CT-based response assessment (anatomic imaging):
CT focuses on size and structure. It can be helpful when PET is not appropriate, but residual masses on CT may represent scar tissue rather than active disease, especially in lymphoma. -
MRI:
MRI can provide excellent soft-tissue detail and is preferred for certain body regions (for example, brain, spine, pelvis) and for specific clinical questions. It generally does not replace PET for metabolic response in FDG-avid lymphoma but may be more informative in selected scenarios. -
Biopsy (tissue confirmation):
When imaging is uncertain and results would change management, biopsy can clarify whether uptake represents viable cancer, inflammation, infection, or another process. Feasibility depends on lesion location and patient factors. -
Clinical assessment and labs:
Symptoms, exam findings, blood counts, inflammatory markers, and disease-specific tests can support or challenge imaging impressions. In some cases, these are prioritized over repeated imaging. -
Observation / active surveillance:
In selected situations—especially when findings are low-level, stable, or clinically low concern—care teams may choose close observation with planned reassessment. Whether this is appropriate varies by clinician and case. -
Other PET tracers or functional imaging approaches:
FDG is the most common tracer in oncology, but alternative tracers exist for specific cancers and questions. Availability and indications vary. -
Emerging biomarkers (for example, circulating tumor DNA):
Some centers use blood-based biomarkers in research or selected clinical contexts. How these compare with PET depends on disease type, test availability, and evidence base.
Overall, Deauville score is most useful when FDG PET is already the right test and when the care team wants a consistent, widely understood way to communicate PET response.
Deauville score Common questions (FAQ)
Q: What do Deauville score values generally mean?
Deauville score compares lesion uptake to mediastinum and liver. Lower scores generally indicate uptake at or below reference tissues, while higher scores indicate uptake above liver. The practical meaning depends on timing, lymphoma subtype, and the full clinical context.
Q: Is getting the scan painful?
The scan itself is usually not painful. You may feel a brief needle stick for the tracer injection, and some people find lying still uncomfortable. If you have pain issues or mobility limitations, tell the imaging team so they can position you safely.
Q: Do I need anesthesia or sedation for a PET/CT used for Deauville score?
Most adults do not need anesthesia. Sedation may be considered in select situations, such as severe claustrophobia or difficulty remaining still, and practices vary by facility. Pediatric imaging may follow different protocols.
Q: Does Deauville score tell me for sure if cancer is gone?
It is not a guarantee. FDG uptake can decrease with effective treatment, but inflammation can also cause uptake, and some cancers may not be strongly FDG-avid. Clinicians interpret the score alongside other information, and sometimes additional tests are needed.
Q: Can infections or recent vaccines affect the Deauville score?
They can affect FDG PET uptake in lymph nodes or tissues and may complicate interpretation. Imaging teams often ask about recent illness, vaccinations, surgeries, or inflammatory conditions. How much this matters varies by clinician and case.
Q: How long does the appointment take and when are results available?
PET/CT visits commonly involve preparation, tracer uptake time, and scanning, so the total visit can be longer than many other imaging tests. Results timing varies by facility workflow and whether prior images are available for comparison. Your care team can explain how and when results are typically communicated.
Q: Is the Deauville score “safe”?
The scoring system itself is simply a reporting method. FDG PET/CT involves exposure to ionizing radiation, and sometimes contrast is used depending on the protocol. Clinicians weigh benefits and risks based on the clinical question and available alternatives.
Q: What side effects can happen from the scan?
Most people have no significant side effects from FDG. If IV contrast is used for the CT portion, side effects can include warmth, nausea, or allergic-type reactions in some individuals, and kidney considerations may apply. Facilities screen for contrast risks and prior reactions.
Q: How much does a PET/CT for Deauville score cost?
Costs vary widely by country, facility, insurance coverage, and whether the scan is bundled with other services. Out-of-pocket costs also vary based on deductibles and authorization requirements. Billing offices can often provide an estimate before the scan.
Q: Will the scan or Deauville score affect fertility or pregnancy?
FDG PET/CT uses radiation, so pregnancy status is an important safety consideration. Fertility effects are not typically discussed as a direct consequence of a single diagnostic scan, but overall treatment plans in oncology can affect fertility. Patients who are pregnant, could be pregnant, or are planning pregnancy should discuss imaging options and timing with their care team.